STOCKHOLM, March 31,
2023 /PRNewswire/ -- Calliditas Therapeutics
AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today
announced its management's participation in the following investor
conferences:
- The Guggenheim Genomic Medicines and Rare Disease Days
Conference, which is being held in person April 3 at the Lotte New York Palace. Calliditas
CEO Renee Aguiar-Lucander will
participate in a company fireside chat and there will also be a KOL
Panel regarding the evolution of IgA nephropathy
treatment.
- The Kempen Life Sciences Conference, which will be held in
person in Amsterdam on
April 25 - 26.
Details for both the IgA Nephropathy KOL panel and fireside chat
at the Guggenheim conference are as follows:
KOL Panel: The Evolution of IgA Nephropathy Treatment: Embracing
Change for Better Patient Outcomes
Date: Monday, April 3, 2023
Time: 8:00 am ET / 2:00 pm CET
Calliditas Fireside Chat
Date: Monday, April 3, 2023
Time: 9:00 am ET / 3:00 pm CET
The company will also hold 1x1 meetings with investors at both
conferences.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on March 31, 2023 at 5:00
p.m. CET.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, developed under the name Nefecon, has been granted
accelerated approval by the FDA under the trade name
TARPEYO® and conditional marketing authorization by the
European Commission under the trade name Kinpeygo®.
Kinpeygo is being commercialized in the European Union Member
States by Calliditas' partner, STADA Arzneimittel AG. Additionally,
Calliditas is conducting a Phase 2b/3
clinical trial in primary biliary cholangitis and a Phase 2
proof-of-concept trial in head and neck cancer with its NOX
inhibitor product candidate, setanaxib. Calliditas' common shares
are listed on Nasdaq Stockholm (ticker: CALTX) and its American
Depositary Shares are listed on the Nasdaq Global Select Market
(ticker: CALT).
The following files are available for download:
https://mb.cision.com/Main/16574/3745116/1959896.pdf
|
Conferences Press
Release Eng
|
View original
content:https://www.prnewswire.com/news-releases/calliditas-to-participate-in-upcoming-investor-conferences-301787171.html
SOURCE Calliditas Therapeutics